Diverse enterprises achieving up to 98% accuracy in invoice data extraction, drastically reducing invoice processing cycle-times, and freeing up FTEs to focus on strategic activities PRINCETON, N.J.–(BUSINESS WIRE)–#ai–Zycus, a global leader in AI-driven Source-to-Pay software solutions, announced today that its AI-powered, self-learning
Principal Investigator of the HopES Sarcoma Study Recommended Continuation of the Trial BEDMINSTER, N.J.–(BUSINESS WIRE)–$TYME—Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today a positive outcome of an interim futility review for the HopES Sarcoma
Early-stage and adverse delinquency rates increased for the second consecutive month – high correlation to geographies most impacted by COVID-19 All 50 states logged year-over-year increases in overall delinquencies this May Over 75% of U.S. metro areas experienced an increase in serious
SWEDESBORO, N.J.–(BUSINESS WIRE)–#CompoundingPharmacy—Wedgewood Pharmacy has completed the acquisition of Wildlife Pharmaceuticals, Inc., Windsor, Colorado, and its wholly-owned pharmacy subsidiary, ZooPharm, Laramie, Wyoming. The companies serve veterinarians and patients in the wildlife and zoo markets. ZooPharm is a veterinary compounding pharmacy that provides
WHIPPANY, N.J.–(BUSINESS WIRE)–Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today. Moore spent the last six years in senior communications roles at Deloitte, most recently
Majesco shareholders to receive $16.00 in cash per share Transaction provides a significant cash premium to Majesco shareholders Transaction Expected to Close by the End of 2020 MORRISTOWN, N.J.–(BUSINESS WIRE)–Majesco (NASDAQ: MJCO), a global leader of cloud insurance software solutions for insurance
CheckMate -743 is the first and only Phase 3 trial in which first-line immunotherapy treatment improved survival in patients with malignant pleural mesothelioma With these positive results, Opdivo plus Yervoy has now shown clinical benefit in six different tumor types, including durable,
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings of “a-” of Junto Resseguros S.A. (Junto Re) and Junto Seguros S.A. (Junto Seg) (collectively referred to as Junto). The outlook of these
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has placed under review with developing implications the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” of Third Point Reinsurance Company Ltd. (Bermuda) and Third Point Reinsurance (USA) Ltd. (Bermuda).